EDESA BIOTECH, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
EDESA BIOTECH, INC. (EDSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.18% for the 12-month period ending 2024-09-30, per its 10-K filed 2024-12-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2024-12-13
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.18%, a 0.00% change from fiscal 2023.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.18%, a 64.57% increase from fiscal 2022.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 2.54%, a 182.22% increase from fiscal 2021.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 0.90%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|
| 2024-09-30 | 4.18% 10-K · filed 2024-12-13 | ||
| 2023-09-30 | 4.18% 10-K · filed 2023-12-15 | ||
| 2023-06-30 | 4.18% 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | 4.18% 10-Q · filed 2023-05-11 | ||
| 2022-09-30 | 2.54% 10-K · filed 2023-12-15 | ||
| 2022-06-30 | 2.54% 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | 2.54% 10-Q · filed 2023-05-11 | ||
| 2021-09-30 | 0.90% 10-K · filed 2022-12-16 | ||
| 2021-06-30 | 0.90% 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | 0.90% 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |